Aethlon Medical logo

Aethlon MedicalNASDAQ: AEMD

Profile

Sector:

Healthcare

Country:

United States

IPO:

04 March 1999

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$5.34 M
-90%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-74%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 16 min ago
$0.38+$0.00(+0.29%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

AEMD Latest News

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit
prnewswire.com08 October 2024 Sentiment: POSITIVE

SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Aethlon Medical, Inc.  (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that James Frakes, Chief Executive Officer and Chief Financial Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, on Tuesday, October 15, 2024 at 4:30 pm ET. To listen to the company presentation, sign up for the conference using this link.

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India
prnewswire.com19 September 2024 Sentiment: POSITIVE

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, the Medanta Institutional Ethics Committee (MIEC) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study).

Aethlon Medical to Present at Virtual Investor Conferences in September
prnewswire.com17 September 2024 Sentiment: POSITIVE

SAN DIEGO , Sept. 17, 2024 /PRNewswire/ -- Aethlon Medical, Inc.  (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that management will present at the following virtual investor conferences in September: September 19-20: Life Sciences Investor Forum: James Frakes, Interim Chief Executive Officer and Chief Financial Officer and Steven LaRosa, MD, Chief Medical Officer, will present a company overview at this conference, hosted by virtualinvestorconferences.com, on Thursday, September 19, 2024 at 1:30 pm ET.

Innovation Driving Cancer's Solid Tumors Market
newsfilecorp.com17 September 2024 Sentiment: POSITIVE

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - September 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at news and developments for the treatment of cancer and solid tumors featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/09170Solid-Tumors-Market.asp According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023.

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
prnewswire.com16 September 2024 Sentiment: POSITIVE

Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 16, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that the Cancer Clinical Trial Unit at Royal Adelaide Hospital was activated on September 10, 2024 to begin screening and enrolling patients in its safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study).

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys
prnewswire.com27 August 2024 Sentiment: POSITIVE

Results Support Future Study of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Association with Function of Retrieved Kidneys SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication in preprint of an in vitro study in bioRxiv on August 24, 2024, entitled, "The Hemopurifier® Removes Extracellular Vesicles and microRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys." Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids, qualities which have potential applications in oncology and infectious diseases, as well as in the organ transplant setting.

The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
newsfilecorp.com12 August 2024 Sentiment: POSITIVE

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology issues a snapshot on recent news and developments for the treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/08120Cancer-Battle.asp The Brainy Insights estimates that the USD 222.71 Billion solid tumor therapeutics market will reach USD 885.44 Billion by 2033.

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial
prnewswire.com12 August 2024 Sentiment: POSITIVE

Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Aug. 12, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on August 6, 2024, the Bellberry Human Research Ethics Committee (BHREC) granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Merck's Keytruda® (pembrolizumab) or Bristol Myers Squibb's Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025.

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024
prnewswire.com06 August 2024 Sentiment: POSITIVE

SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024.

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript
seekingalpha.com27 June 2024 Sentiment: POSITIVE

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day and welcome to the Aethlon Medical Fiscal Year End of 2024 Earnings Conference Call. All participants will be in a listen-only mode.

  • 1(current)

What type of business is Aethlon Medical?

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device for cancer and life-threatening viral infections and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

What sector is Aethlon Medical in?

Aethlon Medical is in the Healthcare sector

What industry is Aethlon Medical in?

Aethlon Medical is in the Medical Devices industry

What country is Aethlon Medical from?

Aethlon Medical is headquartered in United States

When did Aethlon Medical go public?

Aethlon Medical initial public offering (IPO) was on 04 March 1999

What is Aethlon Medical website?

https://www.aethlonmedical.com

Is Aethlon Medical in the S&P 500?

No, Aethlon Medical is not included in the S&P 500 index

Is Aethlon Medical in the NASDAQ 100?

No, Aethlon Medical is not included in the NASDAQ 100 index

Is Aethlon Medical in the Dow Jones?

No, Aethlon Medical is not included in the Dow Jones index

When was Aethlon Medical the previous earnings report?

No data

When does Aethlon Medical earnings report?

The next expected earnings date for Aethlon Medical is 14 November 2024